STRATEGIC NEWS WATCH — June 26, 2026
|
Moderna’s three-wave “horizons” roadmap, unveiled the same week European regulators yanked their backing of Amgen’s Tavneos, frames a market in which pipeline breadth and post-approval scrutiny are reshaping who wins. Today’s top developments:
|
What to Watch
- Amgen Tavneos FDA hearing — With the CHMP now recommending withdrawal of EU authorization, a second negative regulatory outcome in the U.S. could effectively end Tavneos as a commercial asset and force a rethink of Amgen’s rare renal disease portfolio.
- Moderna mFluvisa FDA decision — An agency verdict on the mRNA flu vaccine is expected on or before August 5, 2026; following unanimous advisory committee support, it is the nearest-term catalyst for the 2028 break-even plan and a possible opener for the flu-COVID combination shot.
- Pirtobrutinib EU launch timing — Watch for the formal European Commission decision and Lilly’s launch sequencing; all-lines CLL labeling hands Lilly a positioning edge over first-generation BTK inhibitors that will be tested in pricing and access talks.
- GLP-1 in pulmonary hypertension — Renewed interest hinges on whether early mechanistic signals convert into formal trials; a credible efficacy readout would expand the addressable market for the class well beyond metabolic disease.
- AI-immunology deal momentum — The Immunai-Boehringer tie-up is a marker to watch for whether big pharma keeps outsourcing early target validation to specialized platforms, a trend that could compress discovery timelines across oncology and autoimmune programs.
This brief highlights the edition’s top stories. Read the full June 26, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.